Liver biopsy is the current reliable way of evaluating liver fibrosis. However, no specific sera biomarker could be applied in clinical diagnosis. As the pivotal role of 
or apoptosis. HSC is the critical non-parenchymal cell and also a target of various fibrogenic factors. After stimulation of inflammatory secreted from neighboring cells, the quiescent HSCs transdifferentiate and proliferate into myofibroblast-like cells that adopt proinflammatory and profibrogenic phenotypes (Friedman, 2008; Tsukamoto, Zhu, Asahina, Mann, & Mann, 2011) . Activated HSCs have been implicated in liver fibrosis by producing profibrogenic factors as well as factors that modulate hepatocyte proliferation and by remodeling the ECM (Yin, Evason, Asahina, & Stainier, 2013) , also with immunocytes regulating both the progression and regression of liver fibrosis (Pellicoro, Ramachandran, Iredale, & Fallowfield, 2014) .
Transforming growth factor-β (TGF-β) is considered to be the most potent fibrogenic cytokine in the liver, stimulating ECM protein synthesis and inhibiting its degradation (Friedman, 2008; Tsukamoto et al., 2011) . But to date, none have been validated for clinical use, and potentially promising sera biomarkers are only rarely tested in prediagnostic samples. Thus, to date, liver biopsy remains the most reliable way of evaluating liver fibrosis in patients with hepatitis. However, its inherent risks limit its widespread use.
Osteopontin (OPN) is a multifunctional protein and has been linked to many physiological and pathological events, such as cell migration, cell survival, intractable inflammation, and tumor metastasis. OPN can be found in body fluids including plasma, urine, and breast milk under normal physiological conditions and is secreted by macrophages, T cells, and natural killer T cells. A variety of inflammatory diseases, including multiple sclerosis (Chabas et al., 2001; Steinman & Zamvil, 2003) , rheumatoid arthritis (RA) (Ohshima et al., 2002; Yumoto et al., 2002) , and atherosclerosis (Bruemmer et al., 2003; Matsui et al., 2003) , are associated with the high OPN expression. Importantly, OPN overexpression is associated with various liver diseases (Cui et al., 2015; Diao et al., 2004) . In nonalcoholic steatohepatitis, OPN has been implicated in the promotion of cirrhosis (Syn et al., 2011) . Binding of OPN to surface receptors stimulates cell adhesion, migration, tissue remodeling, and tumor metastasis (Senger, Brown, Perruzzi, Papadopoulossergiou, & Vandewater, 1995; Uchinaka et al., 2015; Uede, 2011; Yamamoto et al., 2003) .
The full-length form of OPN (FL-OPN), which contains an Arg-GlyAsp (RGD) sequence, has diverse functions, including activation of T cells and macrophages, cell adhesion, chemotaxis, and immunomodulation through interaction with integrins such as αvβ3 and αvβ5 (Uchinaka et al., 2015; Uede, 2011; Yamamoto et al., 2003) .
However, cleavage of OPN by thrombin exposes an additional integrin-binding motif, SVVYGLR (SLAYGLR in mice), promoting the cell adherence of RGD-independent cells and a survival advantage to cells expressing α4β1 and α9β1 integrins (Senger et al., 1995; Smith & Giachelli, 1998; Smith et al., 1996; Yamaguchi et al., 2013) .
In mice, the thrombin-cleaved form of OPN (Thr-OPN) has been implicated in the pathogenesis of alcoholic hepatitis, ConA-induced hepatitis, and RA (Diao et al., 2004; Morales-Ibanez et al., 2013) .
Moreover, a recent study showed that Thr-OPN enhanced the synthesis of type III collagen in myocardial fibrosis in a rat model of ischemic cardiomyopathy (Uchinaka et al., 2015) .
However, there is limited information on the role of Thr-OPN in human disease, and not much is still known about the function of Thr-OPN in hepatic fibrosis progression. Therefore, in this study, we investigated the contribution of Thr-OPN to liver fibrosis and assessed whether Thr-OPN could be potentially used to stratify liver fibrosis severity.
| MATERIALS AND METHODS

| Human specimen collection
All patients involved in the study were admitted to the First Affiliated Hospital, School of Medicine, Zhejiang University (China) for diagnosis and treatment from January 2015 to August 2015.
This study was approved by the Institutional Review Board of the First Affiliated Hospital, School of Medicine, Zhejiang University (reference number 2015-311). Written consent was obtained from each patient before the procedure after full explanation of the purpose of the study. All patients were examined by ultrasound and/or computed tomography scans to detect and diagnose LC.
Patients diagnosed with hepatocellular carcinoma were excluded in the study. Moreover, patients coinfected with human immunodeficiency virus, hepatitis A virus, hepatitis C virus or hepatitis D virus, or patients with resolved viral hepatitis were also excluded.
In this study, 22 patients with LC group resulting from chronic hepatitis B (CHB) infection, and 36 patients with CHB without cirrhosis (CHB group) were screened. In addition, 30 healthy volunteers matched for age and sex were recruited as healthy controls (HC). The detailed information for all patients including age and sex are provided in Supporting Information Table S1 .
Plasma was collected from all patients in each group, and percutaneous liver biopsy using disposable needles (18 g × 16 cm, 22 mm penetration depth; Bard Max-Core, Tempe, AZ) was performed on selected patients in each group. Mice were killed at 48 hr after the last injection.
| Animals
| Preparation of Thr-OPN
Human Thr-OPN was prepared by thrombin-mediated cleavage of recombinant human FL-OPN (R&D) at 10 μg FL-OPN per 1 U of the enzyme at 37°C for 1 hr.
| The details of the other methods including liver pathology
Immunohistochemical staining, cell culture, treatment, proliferation assay, migration assay, western blot analysis, analysis of messenger RNA expression, and the ELISA assays were described in the Supporting Information Materials and Methods
| Statistical analysis
All data were expressed as the mean ± standard deviation. SPSS17.0 statistical software was used for statistical analysis. Statistical significance among different groups was analyzed by one-way analysis of variance, and categorical variables were analyzed by Fisher's exact test or Rank sum test. Pearson's correlation analysis was performed for normally distributed variables. Statistical significance was set at p < 0.05.
| RESULTS
| Increased Thr-OPN expression in patients with LC
Previous studies have shown that FL-OPN expression is increased in patients with CHB (Ge et al., 2015) . However, plasma Thr-OPN levels have not been reported in patients with CHB and LC. We found that Thr-OPN levels were significantly increased only in the patients with LC compared with those in the patients with CHB (p = 0.0027) and HCs (p = 0.0015). There was no obvious difference in Thr-OPN levels between patients with CHB and HCs (p = 0.886; Figure 1a ). Meanwhile, FL-OPN levels were significantly higher in patients with LC than those in patients with CHB (p = 0.006). However, in contrast to the patterns of Thr-OPN expression, FL-OPN levels were increased in the CHB group compared with those in the HC group (p = 0.007). There was a sequential increase in plasma FL-OPN expression across the HC group, patients CHB, and LC ( Figure 1a ). Moreover, in the liver of patients with CHB, inflammatory cell infiltration was observed (Figure 1b) , and the Alanine transaminase levels were significantly increased (Supporting Information Table S1 ). Furthermore, the degree of fibrosis was exacerbated significantly in the liver of patients with LC ( Figure 1b Figure S1b ). Importantly, the correlation coefficients between Thr-OPN levels and the three biomarkers were higher than those between FL-OPN and the three biomarkers (Supporting Information Figure S1b and S1c).
TGF-β stimulates the synthesis of ECM proteins, inhibits their degradation, and is considered to be the most potent fibrogenic cytokine in the liver (Friedman, 2008; Tsukamoto et al., 2011) . Thr-OPN levels also showed a significantly positive correlation with TGF-β expression (r = 0.6080, p < 0.001; Supporting Information Figure S2a ). In addition, expression of tumor necrosis factor (TNF)-α, the important inflammatory cytokine, was increased in patients with both CHB and LC compared with those in HCs. However, there was no significant correlation between plasma Thr-OPN and TNF-α expression (r = 0.0716, p = 0.5766; Supporting Information Figure S2b ). per high-power field was calculated and compared. Compared with normal control and CCl 4 -once the group, the IOD value was significantly increased in the CCl 4 -six times, and CCl 4 -eight times groups (all p < 0.001). Notably, the IOD value was significantly higher in the CCl 4 -eight times group than that in CCl 4 -six times group (p < 0.001; Figure 2b ), which suggested a significant progression of liver fibrosis after six times and eight times injection.
To investigate the effect of Thr-OPN and FL-OPN in liver fibrosis, we detected the levels of Thr-OPN and FL-OPN in liver tissue. As shown in Figure 2c , Thr-OPN levels in liver tissues were increased in the CCl 4 -once group compared with the normal control mice (p < 0.01). Importantly, Thr-OPN levels in liver tissues exhibited a significant sequential increase across the CCl 4 -once, CCl 4 -six times, and CCl 4 -eight times groups. This trend was consistent with the process of liver fibrosis. In addition, FL-OPN levels were significantly elevated in the CCl 4 -once group compared with the normal control mice (p < 0.001) but were significantly lower in the fibrosis groups (p < 0.001; Supporting Information Figure S2d ). This trend was consistent with the process of liver injury.
Alpha-smooth muscle actin (α-SMA) is an important marker of HSC activation. To further explore the role of Thr-OPN in liver fibrosis, we identified the expression of α-SMA and HSC marker desmin (Troeger et al., 2012) Figure S4a ).
| Thr-OPN exacerbated CCl 4 -induced liver fibrosis
Previous studies reported that a polyclonal antibody (M5Ab, raised against a synthetic peptide-VDVPNGRGDSLAYGLRS) could block the functions of Thr-OPN in mice (Asai et al., 2010; Diao et al., 2004) . To provide direct evidence for the role of Thr-OPN in liver fibrosis, M5Ab was used in CCl 4 -induced liver fibrosis, and M1Ab was used as the control. As shown in Figure 3a and Supporting Information Figure S4b , Masson's trichrome staining showed that liver fibrosis was alleviated in M5Ab group versus M1Ab group. Moreover, a similar result was observed in the expression of a-SMA in mice liver (Figure 3b ; Supporting Information Figure S4b ). In addition, a cryptic epitope of OPN exposed by thrombin cleavage (VDVPNGRGDSLAYGLRS, M5 peptide) was used to reflect the degree and progression of liver fibrosis in OPNdeficient and wild-type mice. We found that liver fibrosis was significantly decreased in OPN-deficient mice compared with that in wild-type mice after eight injections of CCl 4 (Figure 3c ; Supporting Information Figure   S4c ). Interestingly, administration of the M5 peptide significantly increased the degree of liver fibrosis in OPN-deficient mice (Figure 3c ; Supporting Information Figure S4c ). In contrast, the administration of control peptide (M1 peptide) did not increase liver fibrosis in OPNdeficient mice (Figure 3c ; Supporting Information Figure S4c ). Figure S4d ).
| Thr-OPN promoted the activation, proliferation, and migration of HSCs
| Thr-OPN activated HSCs by α9 and α4 integrins that presented high expressions in liver fibrosis of both patients and the mice model
Cleavage of OPN by thrombin exposes an additional integrin-binding motif (SVVYGLR sequence) that is SLAYGLR in mice, thereby promoting the adherence of cells expressing α4 and α9 integrins (Senger et al., 1995) . Expression of both α9 and α4 in liver tissues was and activation (Diao et al., 2012; Urtasun et al., 2012; Zhang et al., 2015) . Thus, we analyzed the expression of crucial proteins involved in HSCs activation after Thr-OPN stimulation, such as p38, extracellular signal-regulated kinase (Erk) 1/2, c-Jun N-terminal kinase (JNK), and NF-κB p65. First, our laboratory data revealed that the changes in p38, Erk1/2, JNK, and NF-κb p65 of HSCs were increased after Thr-OPN stimulation. After the blockage by integrins α9 and α4 antibodies, the expressions of the total protein or the phosphorylation of p38, Erk1/2, JNK, and NF-κb p65 were inhibited (Figure 6a ; Supporting Information Figure S5b ). To further confirm the signaling pathway of HSCs activation after Thr-OPN stimulation, protein inhibitors of MAPK and NF-κb signaling pathways were used. In genome and protein expression level, we found that α-SMA and col1a expressions of HSC after Thr-OPN stimulation were higher than the controls. However, the elevated α-SMA and col1a expressions of HSC were inhibited with the inhibitor of p38, Erk1/2, and NF-κb, but not the inhibitor of JNK (Figure 6b-d) .
| DISCUSSION
In the current study, we examined whether Thr-OPN played a pivotal role in the pathogenesis of liver fibrosis. We found higher expression of Thr-OPN in patients with LC compared with that in patients with CHB, whereas there was no difference between the levels detected in patients with CHB and healthy volunteers. Importantly, Thr-OPN level was positively correlated to the degree of liver fibrosis. Therefore, we investigated the contribution of Thr-OPN to LC. We found that Thr-OPN promoted the activation, function, and proliferation of HSC cells, and played a pivotal role in the progression of liver fibrosis both in vitro and in vivo.
Histopathological examination of percutaneous biopsies is the "gold standard" method for the diagnosis of LC; however, this approach is limited by the invasive nature of the method. Previous reports have indicated that human plasma cytokines, such as TGF-β and IL-17, are gradually elevated during the progression from hepatitis to LC (Matsue et al., 2015; Yu et al., 2014) , whereas few cytokines are elevated only in liver fibrosis but not by the process of inflammation. To date, noninvasive markers (plasma cytokines) of fibrosis have been validated for clinical use, and potentially promising biomarkers are only rarely tested in prediagnostic samples. We found that plasma Thr-OPN was significantly increased in patients with LC, whereas there was no difference in Thr-OPN levels in patients with CHB and healthy volunteers. Relevant to this investigation, a recent study reported that Thr-OPN enhances the synthesis of collagen type III in myocardial fibrosis in rats (Uchinaka et al., 2015) . We also found that Thr-OPN levels were remarkably elevated in the liver tissue in the CCl 4 -induced liver fibrosis mouse model. In our preliminary experiment, we found that ALT level was sharply increased without liver fibrosis in acute liver injury induced by CCl 4 or ConA in mice, However, multiple and repeated stimulations induced a low and more adapted response of liver injury. Therefore, mice could recover from liver injury once they lived through the attack. And also, it showed an attenuated elevated ALT level after CCl 4 -six times and CCl 4 -eight times. Interestingly, our in vivo experiments also indicated that the changes in Thr-OPN levels in liver tissues were consistent with the degree of liver fibrosis. These observations further confirmed the crucial role of Thr-OPN in the progression of liver fibrosis. Thus, Thr-OPN was implicated as a predictive factor for liver fibrosis.
A polyclonal antibody (M5Ab) raised against a synthetic peptide (a cryptic epitope of OPN exposed by thrombin cleavage, VDVPNGRGDSLAYGLRS, M5 peptide) has been shown to block the functions of Thr-OPN in mice (Asai et al., 2010; Diao et al., 2004; Diao et al., 2008) . In ConA-induced hepatitis, OPN-deficient mice and M5Ab were used to identify the function of Thr-OPN because OPNdeficient mice were refractory to Con A-induced hepatitis, and Thr-OPN blockage by M5Ab also could ameliorate liver injury (Diao et al., 2008) . In contrast, the M1Ab, which was a polyclonal antibody raised against the M1 peptide (LPVKVTDSGSSEEKL) that formed the amino-terminal portion of murine OPN, did not block the functions of Thr-OPN (Diao et al., 2004; Kon et al., 2002) , and the M1Ab was used as control antibody of M5Ab in a series of studies (Asai et al., 2010; Diao et al., 2004) . In our study, we found that only M5Ab, not M1Ab, alleviated CCl 4 -induced liver fibrosis in wild-type mice.
Furthermore, previous studies had shown that this synthetic M5 peptide functions in the same way as Thr-OPN in cell culture (Cui et al., 2015; Yamamoto et al., 2003) . Thus, the M5 peptide was used to verify the function of Thr-OPN in the progression of liver fibrosis, and the M1 peptide was used as the control. We found that liver fibrosis was significantly alleviated in OPN-deficient mice compared with that in wild-type mice. Interestingly, when the M5 peptide was administered, liver fibrosis was significantly exacerbated in OPNdeficient mice, whereas the control M1 peptides had no significant effect. These data directly indicated that Thr-OPN was critically involved in the pathogenesis of liver fibrosis.
In our study, the expression of Thr-OPN was positively correlated with plasma TGF-β levels, suggesting that Thr-OPN was also important in the progression of liver fibrosis. Furthermore, Thr-OPN administration induced higher expression of α-SMA, desmin, TGF-β, and collagen 1a, as well as a faster growth rate in HSCs compared with the effects of FL-OPN administration. Not only did these data suggest that Thr-OPN promoted HSC activation, proliferation and contributed to liver fibrosis, but also that Thr-OPN possessed a more powerful capacity in this regard than FL-OPN. Recent reports indicated that plasma FL-OPN levels were elevated in LC (Matsue et al., 2015; Syn et al., 2011; Zhao et al., 2008) via the activation of HSCs (Urtasun et al., 2012; Xiao et al., 2012) . In our study, we also found a sequential increase in plasma FL-OPN expression across the HC group, patients with CHB, and LC; however, in contrast to the patterns of FL-OPN expression, Thr-OPN levels were significantly increased only in the patients with LC compared with those in the patients with CHB and HCs. There was no obvious difference in Thr-OPN levels between patients with CHB and HCs. OPN interacted with a variety of cell surface receptors, including αvβ3, αvβ5, α4β1, and α8β1 integrins, as well as CD44 to stimulate cell adhesion, migration, chemotaxis, and tissue remodeling, as well as cell survival and inflammatory cell chemoattraction and tumor metastasis (Bataller & Brenner, 2005; Senger et al., 1995; Uchinaka et al., 2015; Uede, 2011; Yamamoto et al., 2003) . The previous study indicated that αvβ3 integrin antibody blocked the increase of collagen-I expression after OPN stimulation, but neutralization of other integrins (i.e. β1, β5, and β6) failed to prevent the increase of collagen-I (Uchinaka et al., 2015) . Both FL-OPN and Thr-OPN bound to α4 integrin, whereas only Thr-OPN bound to α9 integrin via SVVYGLR sequence that was exposed by thrombin-mediated cleavage (Green, Ludbrook, Miller, Horgan, & Barry, 2001; Smith & Giachelli, 1998) . Thr-OPN performed functions such as promoting cell adhesion, migration, and the production of α-SMA and collagen through its interactions with α4β1 and α9β1 integrins (Senger et al., 1995; Uchinaka et al., 2015; Uede, 2011; Yamamoto et al., 2003) . In this study, we found higher expression of both α4 and α9 integrins in liver tissues of patients with LC compared with that in patients with CHB. The expression of α4 and α9 integrins in the mouse livers also exhibited a sustained increase in the progression of liver fibrosis at both the mRNA and protein levels.
Furthermore, we also found that the activated HSCs expressed higher levels of α4 and α9 integrins after Thr-OPN stimulation compared with the levels detected after FL-OPN stimulation in vitro.
Moreover, α9β1 and α4β1 antibodies blocked both α-SMA and col1a expressions of HSCs after Thr-OPN stimulation. In addition, we found that α-SMA and col1a expressions of HSC after Thr-OPN stimulation were inhibited by the inhibitor of p38, Erk1/2, and NF-κb.
However, inhibition is slight with JNK inhibitor, which could be due to the crosstalk with other pathways. These observations indicated that Thr-OPN was involved in promoting the progression of liver fibrosis via a positive feedback mechanism (Supporting Information Figure S5c ).
The activation, function, and proliferation of HSCs are promoted by Thr-OPN via MAP kinase and NF-kB signal pathways when interacted with α9 and α4 integrin receptors. Besides, Thr-OPN is implicated in many other diseases. It was reported that Thr-OPN could regulate hemopoietic stem and progenitor cell functions through interactions with integrins (Grassinger et al., 2009) . Also, administration of Thr-OPN did not affect preterm brain injury, but OPN-derived peptides increased the severity of brain injury in the preterm brain injury model (Albertsson et al., 2014) . Shio et al. (2010) found that thrombin-cleaved OPN was also found increased in the urine of patients with RA, which may reflect the severity of active inflammatory arthritis.
In conclusion, compared with CHB patients, Thr-OPN was expressed at higher levels in patients with LC, whereas there was CUI ET AL.
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no difference in the levels detected in patients with CHB and healthy volunteers. Importantly, Thr-OPN level was positively correlated with liver fibrosis. Moreover, Thr-OPN was involved in liver fibrosis progression both in vitro and in vivo. In addition, Thr-OPN induced HSCs activation by higher expression of α4 and α9 integrins via MAP kinase and NF-κB signaling pathway. These results suggested that Thr-OPN, not FL-OPN, was critically involved in the pathogenesis of liver fibrosis by α9 and α4 integrins via MAP kinase and NF-κB signaling pathway, thus representing a novel diagnostic biomarker and treatment target for LC.
